Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.

Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.